Butyrolactone I, ATP-competitive cyclin-dependent kinase (CDK) inhibitor

Be the first to review this product! Submit a review

|

(1 Publication)

MW 424.4 Da, Purity >97%. Cell permeable, selective, ATP-competitive CDK inhibitor. Inhibits CDC2, CDK2, and CDK5. Inhibits the cell cycle at G1/S and G2/M. Apoptotic and antitumor activity.

View Alternative Names

CCNB, CCNB1_HUMAN, CCNE, CCNE1_HUMAN, CCNE2 protein, CDC28, CDC28A, CDC2A, CDK1_HUMAN, CDK2_HUMAN, CDKN1, CDKN2, CELL CYCLE CONTROLLER CDC2, CYC E2, Cdc 2, Cell Divsion Cycle 2 Protein, Cell devision kinase 2, Cell division control protein 2, Cell division control protein 2 homolog, Cell division cycle 2 G1 to S and G2 to M, Cell division protein kinase 1, Cell division protein kinase 2, Cyclin B1, Cyclin E1, Cyclin Es, Cyclin Et, Cyclin-dependent kinase 1, Cyclin-dependent kinase 2, CyclinE, CyclinE2, DKFZp686L20222, G1/S specific cyclin E, G1/S specific cyclin E2, G1/S-specific cyclin-E1, G2 mitotic specific cyclin B1, G2/mitotic-specific cyclin-B1, MGC111195, MPF, P34CDC2, cdc2-related protein kinase, cyclin E variant ex5del, cyclin E variant ex7del, cyclin dependent kinase 2-alpha, kinase Cdc2, p33 protein kinase, p33(CDK2), p34 Cdk1, p34 protein kinase